Current and Prospective Strategies for Advancing the Targeted Delivery of CRISPR/Cas System Via Extracellular Vesicles

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Jun 8

PMID 37291577

Authors

Xiaowen Huang

Aifang Li

Peng Xu

Yangfan Yu

Shuxuan Li

Lina Hu

Shuying Feng

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs) have emerged as a promising platform for gene delivery owing to their natural properties and phenomenal functions, being able to circumvent the significant challenges associated with toxicity, problematic biocompatibility, and immunogenicity of the standard approaches. These features are of particularly interest for targeted delivery of the emerging clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) systems. However, the current efficiency of EV-meditated transport of CRISPR/Cas components remains insufficient due to numerous exogenous and endogenous barriers. Here, we comprehensively reviewed the current status of EV-based CRISPR/Cas delivery systems. In particular, we explored various strategies and methodologies available to potentially improve the loading capacity, safety, stability, targeting, and tracking for EV-based CRISPR/Cas system delivery. Additionally, we hypothesise the future avenues for the development of EV-based delivery systems that could pave the way for novel clinically valuable gene delivery approaches, and may potentially bridge the gap between gene editing technologies and the laboratory/clinical application of gene therapies.

Citing Articles

The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy.

Lusta K, Churov A, Beloyartsev D, Golovyuk A, Lee A, Sukhorukov V Discov Nano. 2024; 19(1):179.

PMID: 39532781 PMC: 11557815. DOI: 10.1186/s11671-024-04149-8.

Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis.

Jia S, Liang R, Chen J, Liao S, Lin J, Li W Cell Mol Biol Lett. 2024; 29(1):64.

PMID: 38698311 PMC: 11067114. DOI: 10.1186/s11658-024-00581-x.

Extracellular Vesicles: A Crucial Player in the Intestinal Microenvironment and Beyond.

Wang S, Luo J, Wang H, Chen T, Sun J, Xi Q Int J Mol Sci. 2024; 25(6).

PMID: 38542448 PMC: 10970531. DOI: 10.3390/ijms25063478.

Global research trends in CRISPR-related technologies associated with extracellular vesicles from 2015 to 2022: a bibliometric, dynamic, and visualized study.

Lin J, Jia S, Jiao Z, Chen J, Li W, Cao F Cell Mol Biol Lett. 2023; 28(1):99.

PMID: 38041049 PMC: 10693129. DOI: 10.1186/s11658-023-00507-z.

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy.

Dubey A, Mostafavi E Front Chem. 2023; 11:1259435.

PMID: 37841202 PMC: 10568484. DOI: 10.3389/fchem.2023.1259435.

References

Heath N, Osteikoetxea X, de Oliveria T, Lazaro-Ibanez E, Shatnyeva O, Schindler C . Endosomal escape enhancing compounds facilitate functional delivery of extracellular vesicle cargo. Nanomedicine (Lond). 2019; 14(21):2799-2814. DOI: 10.2217/nnm-2019-0061. View

Crewe C, Funcke J, Li S, Joffin N, Gliniak C, Ghaben A . Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 2021; 33(9):1853-1868.e11. PMC: 8429176. DOI: 10.1016/j.cmet.2021.08.002. View

Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A . Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation time . Asian J Pharm Sci. 2021; 16(4):444-458. PMC: 8520042. DOI: 10.1016/j.ajps.2020.07.005. View

Zhang X, Xu Q, Zi Z, Liu Z, Wan C, Crisman L . Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications. Dev Cell. 2020; 55(6):784-801.e9. PMC: 9719439. DOI: 10.1016/j.devcel.2020.11.007. View

Xu X, Liang Y, Li X, Ouyang K, Wang M, Cao T . Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2020; 269:120539. DOI: 10.1016/j.biomaterials.2020.120539. View

Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang J . Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Mol Ther. 2019; 28(2):536-547. PMC: 7001084. DOI: 10.1016/j.ymthe.2019.11.020. View

Kim K, Park J, Sohn Y, Oh C, Park J, Yuk J . Stability of Plant Leaf-Derived Extracellular Vesicles According to Preservative and Storage Temperature. Pharmaceutics. 2022; 14(2). PMC: 8879201. DOI: 10.3390/pharmaceutics14020457. View

Yan J, Shun M, Zhang Y, Hao C, Skowronski J . HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells. Proc Natl Acad Sci U S A. 2019; 116(19):9568-9577. PMC: 6511057. DOI: 10.1073/pnas.1818401116. View

Hamilton J, Tsuchida C, Nguyen D, Shy B, McGarrigle E, Sandoval Espinoza C . Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021; 35(9):109207. PMC: 8236216. DOI: 10.1016/j.celrep.2021.109207. View

10.

Lainscek D, Kadunc L, Keber M, Bratkovic I, Romih R, Jerala R . Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol. 2018; 7(12):2715-2725. DOI: 10.1021/acssynbio.8b00192. View

11.

Han C, Kang H, Yi J, Kang M, Lee H, Kwon Y . Single-vesicle imaging and co-localization analysis for tetraspanin profiling of individual extracellular vesicles. J Extracell Vesicles. 2021; 10(3):e12047. PMC: 7797949. DOI: 10.1002/jev2.12047. View

12.

Debbi L, Guo S, Safina D, Levenberg S . Boosting extracellular vesicle secretion. Biotechnol Adv. 2022; 59:107983. PMC: 9420194. DOI: 10.1016/j.biotechadv.2022.107983. View

13.

Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L . Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. Adv Sci (Weinh). 2018; 5(4):1700611. PMC: 5908366. DOI: 10.1002/advs.201700611. View

14.

Dusoswa S, Horrevorts S, Ambrosini M, Kalay H, Paauw N, Nieuwland R . Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. J Extracell Vesicles. 2019; 8(1):1648995. PMC: 6713149. DOI: 10.1080/20013078.2019.1648995. View

15.

Lazaro-Ibanez E, Faruqu F, Saleh A, Silva A, Wang J, Rak J . Selection of Fluorescent, Bioluminescent, and Radioactive Tracers to Accurately Reflect Extracellular Vesicle Biodistribution . ACS Nano. 2021; 15(2):3212-3227. PMC: 7905875. DOI: 10.1021/acsnano.0c09873. View

16.

Cheng L, Zhang X, Tang J, Lv Q, Liu J . Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. Biomaterials. 2021; 275:120964. DOI: 10.1016/j.biomaterials.2021.120964. View

17.

Somiya M, Kuroda S . Reporter gene assay for membrane fusion of extracellular vesicles. J Extracell Vesicles. 2021; 10(13):e12171. PMC: 8607979. DOI: 10.1002/jev2.12171. View

18.

Wang Q, Ren Y, Mu J, Egilmez N, Zhuang X, Deng Z . Grapefruit-Derived Nanovectors Use an Activated Leukocyte Trafficking Pathway to Deliver Therapeutic Agents to Inflammatory Tumor Sites. Cancer Res. 2015; 75(12):2520-9. PMC: 4470740. DOI: 10.1158/0008-5472.CAN-14-3095. View

19.

Wang J, Yu C, Zhuang J, Qi W, Jiang J, Liu X . The role of phosphatidylserine on the membrane in immunity and blood coagulation. Biomark Res. 2022; 10(1):4. PMC: 8760663. DOI: 10.1186/s40364-021-00346-0. View

20.

Qi H, Liu C, Long L, Ren Y, Zhang S, Chang X . Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy. ACS Nano. 2016; 10(3):3323-33. DOI: 10.1021/acsnano.5b06939. View